Veliparib dihydrochloride

Product Description

Veliparib dihydrochloride is a high affinity PARP-2 and PARP-1 inhibitor (K_i values are 2.9 and 5.2 nM, respectively). Inhibits repair of radiation-induced DNA damage and sensitizes lung cancer cells to radiation. Also increases autophagy and apoptosis in lung cancer cells. Enhances radiation-induced tumor growth delay in mice bearing lung tumor xenografts. Also chemosensitizer. Potentiates effects of temozolomide (Cat. No. 2706) in a mouse melanoma model. Orally bioavailable and brain penetrant.

Solubility

Preparing Stock Solutions for Veliparib dihydrochloride

The following data is based on the product molecular weight 317.21

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.15 mL	15.76 mL	31.52 mL
5 mM	0.63 mL	3.15 mL	6.30 mL
10 mM	0.32 mL	1.58 mL	3.15 mL
50 mM	0.06 mL	0.32 mL	0.63 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Donawho ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin.Cancer Res. 2007 PMID: 17473206
• Albert Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin.Cancer Res. 2007 PMID: 17505006